Highlights Alnylam Pharmaceuticals, Inc. BOERSE MUENCHEN

Equities

DUL

US02043Q1076

Market Closed - BOERSE MUENCHEN Other stock markets 01:13:45 29/06/2024 am IST			5-day change	1st Jan Change
227.5 ^EUR	-1.34%		+46.77%	+28.53%

28/06	UBS Adjusts Price Target on Alnylam Pharmaceuticals to $288 From $253, Maintains Buy Rating	MT
27/06	Stifel Adjusts Price Target on Alnylam Pharmaceuticals to $295 From $215, Maintains Buy Rating	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Sector Update: Health Care Stocks Ease Late Afternoon	26/06	MT
Alnylam Pharmaceuticals Shares Rise as Heart Disease Candidate Meets Primary Endpoint in Late-Stage Study	25/06	MT
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	25/06	MT
Top Midday Gainers	24/06	MT
Alnylam Pharmaceuticals Says Heart Disease Therapy Meets Primary Endpoint in Late-Stage Study	24/06	MT
Alnylam's heart disease drug meets main goal in late-stage study	24/06	RE
Alnylam Pharmaceuticals, Inc. Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations	24/06	CI
Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed	02/05	MT
Earnings Flash (ALNY) ALNYLAM PHARMACEUTICALS Posts Q1 Revenue $494.3M, vs. Street Est of $426.9M	02/05	MT
Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05	CI
Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024	02/05	CI
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of Their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in Additional Latam and APAC Markets Including Australia	30/04	CI
Sector Update: Health Care Stocks Flat to Higher Premarket Monday	08/04	MT
Sector Update: Health Care	08/04	MT
Alnylam Pharmaceuticals Says Phase 2 Trial for Zilebesiran Meets Primary Endpoint	08/04	MT
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension	07/04	CI
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran Is Added to Standard of Care Antihypertensives	05/03	CI
How long will this bullish phase last?	26/02
North American Morning Briefing : Earnings Back in -2-	20/02	DJ
Alnylam Pharmaceuticals' Shares Fall on Q4 Revenue Miss	15/02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Alnylam Pharmaceuticals, Inc. BOERSE MUENCHEN

Equities

DUL

US02043Q1076

Highlights

Filters